Scarica l'app Stockscreener
22.38
3.49%
-0.81
Precedente Chiudi:
$23.19
Aprire:
$23.065
Volume 24 ore:
3.87M
Relative Volume:
1.44
Capitalizzazione di mercato:
$2.83B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-11.08
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
+9.06%
1M Prestazione:
+35.64%
6M Prestazione:
+64.32%
1 anno Prestazione:
+50.20%
Intervallo 1D:
$22.07
$23.56
Intervallo di 1 settimana:
$19.34
$23.56
Portata 52W:
$6.78
$23.56
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
22.38 | 2.93B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
222.00 | 37.03B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
65.32 | 12.16B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
40.63 | 7.68B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
84.11 | 7.38B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.64 | 7.14B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected - simplywall.st
Volume Report: How does 10x Genomics Inc perform in inflationary periods2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - BioSpace
Zacks Industry Outlook Highlights Doximity, 10x Genomics and Omnicell - Yahoo Finance
Revenue Check: What is VERX s P E ratio telling usAnalyst Upgrade & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Inscription Capital LLC Acquires 59,305 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Trading Up 8%Still a Buy? - MarketBeat
10x Genomics Inc (TXG) Trading 6.38% Higher on Jan 20 - GuruFocus
10X Genomics stock hits 52-week high of 21.52 USD - Investing.com
Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? - Benzinga
Sentiment Recap: Is 10x Genomics Inc a strong candidate for buy and hold2025 Momentum Check & Real-Time Buy Signal Alerts - baoquankhu1.vn
Aug Breakouts: Is United States Steel Corporation stock a good pick for beginnersQuarterly Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Ideas: Can 10x Genomics Inc stock outperform in a bear marketJuly 2025 Closing Moves & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG - MarketBeat
Aug Weekly: Whats the fair value of AN2 Therapeutics Inc stockWeekly Investment Summary & Technical Pattern Alert System - baoquankhu1.vn
Wall Street Recap: What is INTA s revenue forecastTrade Performance Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Insider Trends: Will 10x Genomics Inc outperform its industry peersJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - BioSpace
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
10x Genomics (NASDAQ:TXG) Shares Down 8.5%What's Next? - MarketBeat
Cancer Research Institute Launches Transformative AI-Driven Immu - GuruFocus
10x Genomics partners with Dana-Farber to research cancer treatment responses - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research By Investing.com - Investing.com Canada
10x Genomics Launches Study to Advance Research in Blood-Based D - GuruFocus
10x Genomics to Advance Research in Diagnostic Applications of T - GuruFocus
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - PR Newswire
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire
10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus
10x Genomics sees uptick in Q4 revenue despite softer FY sales (TXG:NASDAQ) - Seeking Alpha
10x Genomics (TXG) Achieves Remarkable Progress Despite Economic Challenges - GuruFocus
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - The Malaysian Reserve
Press Release: 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - 富途资讯
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | TXG Stock News - Longbridge
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 32% - 富途牛牛
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
Aug Swings: Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
10x Genomics (NASDAQ:TXG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Will 10x Genomics Inc. stock split attract more investorsJuly 2025 Highlights & Verified Swing Trading Watchlist - Улправда
Published on: 2026-01-10 18:33:58 - moha.gov.vn
10x Genomics (NASDAQ:TXG) Reaches New 12-Month HighShould You Buy? - MarketBeat
10X Genomics stock hits 52-week high at 20.36 USD - Investing.com
10X Genomics stock hits 52-week high at 20.36 USD By Investing.com - Investing.com India
Is 10x Genomics Inc. stock a safe haven asset2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumWeekly Gains Summary & Reliable Entry Point Alerts - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Catalysts & Accurate Intraday Trade Tips - ulpravda.ru
Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Gains Recap: Why 10x Genomics Inc. stock is favored by top institutionsJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - Улправда
Risk Check: How 10x Genomics Inc. stock benefits from strong dollar2025 Market Trends & Accurate Intraday Trading Signals - ulpravda.ru
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10 X Genomics Inc Azioni (TXG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Taich Adam | Chief Financial Officer |
Nov 24 '25 |
Sale |
19.00 |
11,888 |
225,852 |
297,385 |
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
4.00%
1.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):